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inappropriate incision.2 We actually encountered strikingly
severe degeneration of ePTFE at a reoperation 7 years after
the Manouguian procedure. The patch was too stiff to
function as part of the heart valve, although prolapse and
MR were mild in this case. Therefore it appears better not to
use synthetic prosthetic patches that may degenerate later
on. In this regard, bioprosthetic material may also not be a
good choice for the patch. Even allografts are not free from
degeneration. In our experience, patients with an autologous
pericardial patch had better results. Abnormal motion of the
mitral valve or significant MR was not present in any of
them. However, shrinkage and sclerosing change of the
autologous pericardium are also well known. At present, the
ideal patch material for the Manouguian procedure does not
seem to exist. In addition, acceptable morphologic alteration
of the mitral anulus and the anterior leaflet in this procedure
is yet unclear, especially in pediatric patients. Therefore
every patient undergoing the Manouguian procedure needs
careful follow-up.
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Severe life-threatening reactions have been reported in
association with protamine use, including pulmonary hy-
pertension, systemic hypotension, and anaphylactic shock,
as well as thrombocytopenia, granulocytopenia, comple-
ment activation, and cytokine release.1 As an alternative
to protamine administration, a heparin removal device
(HRD, Research Medical Inc., Midvale, Utah) uses a
venovenous extracorporeal circuit with plasma separation
and poly-L-lysine affinity adsorption to remove heparin
from the blood.2 We3 previously reported the first com-
passionate clinical use of the HRD to decrease life-
threatening bleeding in a patient who could not tolerate
protamine. Through large animal studies, we4-6 have since
characterized the performance of the HRD and devel-
oped a heparin clearance mathematical model to deter-
mine the HRD run time needed for a targeted 90%
heparin removal based on first-order exponential deple-
tion. Variables affecting the HRD efficiency, such as
extracorporeal blood flow, sorbent amount, and cannula
placement, have likewise been improved. The HRD re-
turns activated clotting time (ACT) and other measured
coagulation variables to near baseline values in approxi-
mately 30 minutes in adult-sized subjects at the veno-
venous extracorporeal blood flow rate of 1400 ml/min
without any apparent adverse effects on hemodynamics.4-6
From May 6 to May 27, 1997, two patients scheduled for
elective coronary artery bypass grafting had documented
“hypersensitivity” to protamine, and the HRD was used as
an alternative to reverse systemic heparin anticoagulation.
Since the HRD has not been approved by the Food and
Drug Administration, approval for compassionate use was
obtained from the Institutional Review Board of the
University of Texas Medical Branch, Galveston, Texas,
and informed consent was obtained from each patient
before the operation.
Because of persistent angina after a recent myocardial
infarction, a 58-year-old woman underwent cardiac cath-
eterization demonstrating severe three-vessel disease. On
completion of her cardiac catheterization she was given
protamine (4 mg), resulting in dizziness, an urticarial
eruption, and hypotension (74/50 mm Hg). She was
treated with intravenous antihistamines (Benadryl 100
mg) and steroids (Solu-Medrol 125 mg) for a presumed
protamine reaction. She continued to be hypotensive,
despite treatment, and received 1.5 L of crystalloid solu-
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tion and inotropic support. She recovered over 4 to 5
hours and was referred for revascularization. After three-
vessel coronary artery bypass grafting, the patient had
good hemodynamics and was weaned from cardiopulmo-
nary bypass (CPB). To avoid protamine, we used the
HRD. The right atrial venous cannula was removed and
the HRD dual-lumen venovenous cannula was inserted
through the same atriotomy. The distal port was posi-
tioned into the inferior vena cava for drainage and the
proximal port at the level of the right atrium for reinfu-
sion, oriented toward the tricuspid valve to minimize
blood recirculation. Blood flow was controlled by a roller
pump that drained blood from the inferior vena cava and
pumped it through the plasma separator, whose hollow
fibers allow for plasmapheresis. The strongly negatively
charged heparin binds with the strongly positively charged
poly-L-lysine–agarose to remove heparin from the blood.
The heparin-depleted plasma then reenters the hollow
fibers to recombine with the formed elements of the blood
and return to the patient’s right atrium.
The HRD was used at a target flow rate of 1400 ml/min
for 35 minutes as predicted by our mathematical model of
first-order exponential depletion for a targeted 90% hep-
arin removal. No changes in hemodynamics occurred
during the use of the HRD. Heparinized pump blood (700
ml) was infused via the aortic cannula to replace cardiot-
omy suction during the HRD run. Fig. 1 (patient A) shows
the ACT time course at baseline, during the HRD run,
and after the operation. Before and after the HRD run,
fibrin degradation products were less than 5 mg/ml, acti-
vated partial thromboplastin time greater than 150 sec-
onds, and d-dimer less than 0.5 ng/ml. Platelet count was
225,000 ml immediately after CPB, 167,000 ml after the
HRD run, and 272,000 ml 3 hours after the operation. The
plasma free hemoglobin concentration was 19 mg/dl im-
mediately after CPB, 25 mg/dl after the HRD run, and 3
mg/dl 3 hours after the operation. The hematocrit value
showed typical changes related to CPB with hemodilution.
The patient was transferred to the intensive care unit with
chest tube drainage of only 300 ml over the first 6 hours.
No blood products including red blood cells, fresh frozen
plasma, platelets, or clotting factors were given, and there
was no evidence of significant bleeding or identifiable
complications. She was ambulatory on postoperative day
3, discharged day 5, and is doing well 3 months after the
operation.
A 63-year-old (136 kg) woman with a history of
hypertension and insulin-dependent diabetes had left
carotid endarterectomy and three-vessel coronary ar-
tery bypass grafting 7 years ago when profound hypo-
tension and elevated pulmonary pressures developed
immediately after protamine administration, requiring
a right ventricular injection of 300 mg of epinephrine.
The patient recently began having symptoms of conges-
tive heart failure resulting from critical aortic stenosis
and recurrent coronary artery disease. She underwent
aortic valve replacement, a single coronary artery by-
pass graft, and intraaortic balloon pump placement. She
was weaned from CPB after two attempts. The HRD
dual-lumen venovenous cannula was inserted as de-
scribed, and HRD at a flow rate of 1400 ml/min was
used for 68 minutes. A 42-minute HRD run time at
1400 ml/min was initially predicted by the mathematical
model and in retrospect was sufficient; however, the
HRD run was extended because of a perceived increase
in ACT at 40 to 50 minutes. A total of 1800 ml of
heparinized pump blood was infused via the aortic
cannula to replace cardiotomy suction. Fig. 1 (patient
B) shows the time courses for ACT at baseline, during
the HRD run, and after the operation. Before and after
the HRD run, fibrin degradation products were , 5
mg/ml and . 5 , 20 mg/ml, activated partial thrombo-
Fig. 1. ACT time course at baseline, during HRD, and after the operation.
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plastin time was greater than 150 seconds, and d-dimer
was less than 0.5 ng/ml. Platelet count was 138,000 ml
immediately after CPB, 111,000 ml after the HRD run,
and 105,000 ml 24 hours after the operation. Plasma
free hemoglobin concentration was 48 mg/dl immedi-
ately after CPB and 52 mg/dl after the HRD run. The
patient was transferred to the intensive care unit with
chest tube drainage of 1930 ml over the first 24 hours
after the operation (1425 ml/6 hr). She required 5 units
of red blood cells, 75 ml of platelets, and 4 units of fresh
frozen plasma. She recovered and has returned to full
activity at 3 months’ follow-up.
The HRD achieves predictable systemic heparin re-
moval, without causing additional blood cell damage, in
clinical situations in which protamine may be contraindi-
cated. The HRD awaits clinical trials for approval as an
investigational device.
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Notice of correction
In the February 1998 issue of the Journal, in the article by Gammie and associates titled
“Single- Versus Double-Lung Transplantation for Pulmonary Hypertension” (1998;115:397-
403), an error was made. In Table III, the final three entries in the single-lung transplantation
(SLT) column should have been placed in the double-lung transplantation (DLT) column.
